pharmazz

about

Pharmazz, Inc.

Pharmazz, Inc. is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target critical care medicine. The company is developing several clinical-stage product candidates, PMZ-2010, PMZ-1620 and PMZ-2123 for which it holds global marketing rights.

Established in 2010, Pharmazz Inc. is an emerging global pharmaceutical company. Focus of the company is to discover, acquire, develop and market novel pharmaceutical products for use in critical care and hospital settings.

Product Pipeline

Product
Pre-Clinical
Clinical Trial

phase 1

phase 2

phase 3

Market

Hypovolemic Shock (PMZ-2010)

Alzheimer's Disease (PMZ-1620)

Ischemic stroke (PMZ-1620)

Cardiac Arrest (PMZ-2010)

Spinal Cord Injury (PMZ-1620)

Diabetic Ketoacidosis (PMZ-2123)

Post-Operative Pain (PMZ-2010)

Tumor Diagnosis (PMZ-1620)

Products

Hypovolemic Shock

Hypovolemic Shock

Hypovolemic Shock

Postoperative Pain

Cardiac Arrest

Cardiac Arrest

Alzheimer's Disease

Alzheimer's Disease

Ischemic Stroke

Ischemic Stroke

Spinal Cord Injury

Spinal Cord Injury

Tumor Imaging

Tumor Diagnosis

Diabetic Ketoacidosis

Diabetic Ketoacidosis

phase 1

Developing products that are first-in-class with unique mechanism of action that are different from those of existing therapies